Enhancing dendritic cells by inhibiting BCL2

Christopher A G Booth; Andrew A Lane

doi:10.1016/j.trecan.2023.09.007

Enhancing dendritic cells by inhibiting BCL2

Trends Cancer. 2023 Dec;9(12):987-988. doi: 10.1016/j.trecan.2023.09.007. Epub 2023 Sep 30.

Authors

Christopher A G Booth¹, Andrew A Lane²

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: Andrew_Lane@dfci.harvard.edu.

PMID: 37783616
DOI: 10.1016/j.trecan.2023.09.007

Abstract

Dendritic cells play an important role in anticancer immunity by exposing T cells to tumor-associated antigens. In a recent study, Zhao et al. show that BCL2 inhibition improves the ability of dendritic cells to present antigen to T cells and activate their antitumor cytotoxicity.

Keywords: BCL2 inhibition; dendritic cells; immunotherapy.

MeSH terms

Antigens, Neoplasm
Dendritic Cells
Humans
Neoplasms* / drug therapy
Proto-Oncogene Proteins c-bcl-2
T-Lymphocytes

Substances

Antigens, Neoplasm
Proto-Oncogene Proteins c-bcl-2
BCL2 protein, human